SAN DIEGO, May 25, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company focused on developing medicines for the treatment of hepatitis C, announced today that it will present data from a previously conducted cancer study of ANA773, the Company's oral immuno-modulator that acts via the TLR-7 pathway, at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The data from the completed Phase I study is being presented on June 4, 2011 in a poster titled "Phase I Open Label, Dose Escalation Study of ANA773 Tosylate, an Oral Prodrug of a Toll-Like Receptor-7 Agonist, in Patients with Advanced Solid Tumors". The poster will be available on the Company's website at www.anadyspharma.com as of the date of presentation.
In the Phase I cancer study, ANA773 showed a favorable safety and tolerability profile at doses that had desired effects on the innate immune system. A confirmed partial response was achieved in a patient with melanoma and prolonged stable disease was observed in additional patients. A maximum tolerated dose (MTD) was not reached in this study. These results suggest that ANA773 may provide clinical benefit to cancer patients.
"The clinical activity seen with ANA773 in this Phase I oncology study is quite promising," said James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "While Anadys is focusing its development efforts in the area of hepatitis C, we continue to believe that ANA773 holds promise for the treatment of a range of cancer types, particularly in combination with other agents such as monoclonal antibodies that rely on immune mechanisms for activity."
About the Concluded Phase I study of ANA773 in Cancer
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved